Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an announcement.
Shanghai Henlius Biotech, Inc. announced the approval of its application for a Phase 1b/2 clinical trial of HLX43, an antibody-drug conjugate targeting PD-L1, in combination with HANSIZHUANG, for treating advanced/metastatic solid tumors by the National Medical Products Administration. This approval marks a significant step in the company’s development of combination therapies that may offer more effective and safer treatment options. The announcement highlights the potential for a synergistic effect between antibody-drug conjugates and PD-1/L1 monoclonal antibodies, positioning Shanghai Henlius as a pioneer in this therapeutic area.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company focused on developing innovative antibody therapies, including antibody-drug conjugates and monoclonal antibodies, targeting various types of cancers. The company operates in the biopharmaceutical industry and has a market focus on developing treatments for solid tumors and other cancer indications.
YTD Price Performance: -0.63%
Average Trading Volume: 272,719
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$12.8B
For detailed information about 2696 stock, go to TipRanks’ Stock Analysis page.